Wedbush Has Optimistic View of Disc Medicine FY2026 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Wedbush lifted their FY2026 EPS estimates for Disc Medicine in a note issued to investors on Tuesday, January 21st. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($3.96) for the year, up from their prior forecast of ($4.19). Wedbush currently has a “Outperform” rating and a $90.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine’s FY2027 earnings at $2.64 EPS.

A number of other analysts also recently weighed in on IRON. Jefferies Financial Group assumed coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price target for the company. Stifel Nicolaus raised their price target on shares of Disc Medicine from $79.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and set a $118.00 price target on shares of Disc Medicine in a research report on Tuesday. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $66.00 to $110.00 in a research report on Monday, November 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Tuesday, October 15th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $88.50.

Disc Medicine Trading Down 2.6 %

IRON stock opened at $56.99 on Thursday. Disc Medicine has a twelve month low of $25.60 and a twelve month high of $77.60. The company has a market capitalization of $1.70 billion, a P/E ratio of -14.32 and a beta of 0.75. The firm has a 50 day simple moving average of $62.66 and a 200-day simple moving average of $53.72.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15.

Institutional Investors Weigh In On Disc Medicine

Hedge funds and other institutional investors have recently modified their holdings of the stock. Amalgamated Bank raised its stake in shares of Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after purchasing an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after purchasing an additional 337 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Disc Medicine during the third quarter valued at about $131,000. Quantbot Technologies LP bought a new stake in shares of Disc Medicine during the third quarter valued at about $146,000. Finally, Intech Investment Management LLC bought a new stake in shares of Disc Medicine during the third quarter valued at about $228,000. 83.70% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director William Richard White sold 7,136 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John D. Quisel sold 12,791 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $66.01, for a total transaction of $844,333.91. Following the transaction, the chief executive officer now directly owns 72,065 shares of the company’s stock, valued at approximately $4,757,010.65. This trade represents a 15.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 85,758 shares of company stock valued at $5,400,990. 4.24% of the stock is currently owned by company insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.